These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25728682)

  • 21. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
    Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
    Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.
    Hacker KE; Fahey CC; Shinsky SA; Chiang YJ; DiFiore JV; Jha DK; Vo AH; Shavit JA; Davis IJ; Strahl BD; Rathmell WK
    J Biol Chem; 2016 Sep; 291(40):21283-21295. PubMed ID: 27528607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.
    Feng C; Sun Y; Ding G; Wu Z; Jiang H; Wang L; Ding Q; Wen H
    Sci Rep; 2015 Apr; 5():9465. PubMed ID: 25853938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
    Gautam D; Johnson BA; Mac M; Moody CA
    PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A New Chromatin-Cytoskeleton Link in Cancer.
    Giaccia AJ
    Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
    Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
    Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An actin-WHAMM interaction linking SETD2 and autophagy.
    Seervai RNH; Grimm SL; Jangid RK; Tripathi DN; Coarfa C; Walker CL
    Biochem Biophys Res Commun; 2021 Jun; 558():202-208. PubMed ID: 33036756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
    Simon JM; Hacker KE; Singh D; Brannon AR; Parker JS; Weiser M; Ho TH; Kuan PF; Jonasch E; Furey TS; Prins JF; Lieb JD; Rathmell WK; Davis IJ
    Genome Res; 2014 Feb; 24(2):241-50. PubMed ID: 24158655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
    Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
    Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney cancer: SETD2 affects DNA replication.
    Stone L
    Nat Rev Urol; 2015 Apr; 12(4):183. PubMed ID: 25782172
    [No Abstract]   [Full Text] [Related]  

  • 33. SETD2: an epigenetic modifier with tumor suppressor functionality.
    Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
    Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
    Wang J; Wen J; Yi R; Liu F; Zhou J; Liu G; Li Q; Yang Z; Su X
    J BUON; 2015; 20(5):1267-75. PubMed ID: 26537074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-talk between the H3K36me3 and H4K16ac histone epigenetic marks in DNA double-strand break repair.
    Li L; Wang Y
    J Biol Chem; 2017 Jul; 292(28):11951-11959. PubMed ID: 28546430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma.
    Yu M; Qian K; Wang G; Xiao Y; Zhu Y; Ju L
    Front Oncol; 2023; 13():1114461. PubMed ID: 37025591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
    Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
    Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
    Fahey CC; Davis IJ
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress.
    Bleuyard JY; Fournier M; Nakato R; Couturier AM; Katou Y; Ralf C; Hester SS; Dominguez D; Rhodes D; Humphrey TC; Shirahige K; Esashi F
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7671-7676. PubMed ID: 28673974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.